Ascidian Therapeutics

Ascidian Therapeutics is redefining the treatment of disease by rewriting RNA. By editing exons at the RNA level, Ascidian therapies enable precise post-transcriptional editing of genes, resulting in full-length, functional proteins at the right levels, in the right cells, at the right time. With active discovery and preclinical programs in ophthalmology, neurological and neuromuscular disorders, and other rare diseases, Ascidian is opening new therapeutic possibilities for patients in need of breakthroughs. For more information, visit www.ascidian-tx.com

Gene therapy,biotechnology,and rna therapeutics

Ascidian therapeutics operates in the Biotechnology industry.

Ascidian therapeutics's revenue is 11m - 100m

Ascidian therapeutics has 51 - 200 employees.